CCM
APTO

Consonance Capital Management’s Aptose Biosciences, Inc. APTO Stock Holding History

Consonance Capital Management’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,766
Closed -$48M – 47
2020
Q3 		$48M Buy
17,766
+2,277
+15% +$5.68M 5.84% 6
2020
Q2 		$44M Buy
15,489
+2,608
+20% +$8.41M 2.64% 18
2020
Q1 		$34.4M Buy
12,881
+2,276
+21% +$6.79M 2.56% 17
2019
Q4 		$27.1M Buy
+10,605
New +$13.8M 1.65% 25

Other funds holding APTO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Consonance Capital Management's APTO Position: Q4 2020 in Review

Consonance Capital Management sold out of Aptose Biosciences, Inc. (APTO) in Q4 2020, closing a stake of 17,766 shares — an estimated $48M sold.

Consonance Capital Management first reported a position in APTO in Q4 2019 and held it in 4 quarters. The position peaked at $48M in Q3 2020. 65 funds tracked by Wall St. Rank hold APTO as of Q4 2020.

  • Consonance Capital Management reported no remaining Aptose Biosciences, Inc. position as of Q4 2020 after selling out during the quarter.
  • Consonance Capital Management sold 17,766 Aptose Biosciences, Inc. shares in Q4 2020, an estimated $48M.
  • Consonance Capital Management first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 4 quarters.
  • Consonance Capital Management's Aptose Biosciences, Inc. position peaked at $48M in Q3 2020.
  • 65 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q4 2020.

Based on Consonance Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.